Diabetic retinopathy

Ribonucleic acid-based combination therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  LncRNA MEG3, Epicatechin and Matrine (MEG3EM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 14/April/2019,  6.23 am
Ribonucleic acid-based combination therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  LncRNA MEG3, Epicatechin and Matrine (MEG3EM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 14/April/2019,  6.23 am 960 720

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

Ribonucleic acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  LncRNA MIAT, Epicatechin and Matrine (MIATEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/December/2018,  10.00 pm
Ribonucleic acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  LncRNA MIAT, Epicatechin and Matrine (MIATEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/December/2018,  10.00 pm 960 720

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Fasudil, Epicatechin and Matrine (FEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 17/January/2018, 11.41 pm
Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Fasudil, Epicatechin and Matrine (FEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 17/January/2018, 11.41 pm 960 720

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

RNA-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  lncRNA TUG1, Epicatechin and Matrine (TUG1EM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 5/January/2018, 12.04 am
RNA-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  lncRNA TUG1, Epicatechin and Matrine (TUG1EM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 5/January/2018, 12.04 am 960 720

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

Molecular therapy for TIIDM and Metabolic defects:Mesencephalic astrocyte-derived neurotrophic factor (MANF)  increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 21/December/2018, 10.43 pm
Molecular therapy for TIIDM and Metabolic defects:Mesencephalic astrocyte-derived neurotrophic factor (MANF)  increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 21/December/2018, 10.43 pm 960 720

Introduction: What they say A study from the “Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27701, USA; Department of…

read more

Activator protein(AP-1)-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  a chemical compound that induces  AP-1 activity, Epicatechin and Matrine (VAEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/December/2018, 10.32 pm
Activator protein(AP-1)-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  a chemical compound that induces  AP-1 activity, Epicatechin and Matrine (VAEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/December/2018, 10.32 pm 960 720

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more
Start Typing